ID   RAPSN_HUMAN             Reviewed;         412 AA.
AC   Q13702; Q8TDF3; Q9BTD9;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   17-APR-2007, sequence version 4.
DT   28-JUN-2023, entry version 211.
DE   RecName: Full=43 kDa receptor-associated protein of the synapse;
DE            Short=RAPsyn;
DE   AltName: Full=43 kDa postsynaptic protein;
DE   AltName: Full=Acetylcholine receptor-associated 43 kDa protein;
DE   AltName: Full=RING finger protein 205;
GN   Name=RAPSN; Synonyms=RNF205;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=8812503; DOI=10.1006/geno.1996.0409;
RA   Buckel A., Beeson D., James M., Vincent A.;
RT   "Cloning of cDNA encoding human rapsyn and mapping of the RAPSN gene locus
RT   to chromosome 11p11.2-p11.1.";
RL   Genomics 35:613-616(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS CMS11 PRO-14 AND
RP   LYS-88.
RX   PubMed=11791205; DOI=10.1086/339465;
RA   Ohno K., Engel A.G., Shen X.-M., Selcen D., Brengman J., Harper C.M.,
RA   Tsujino A., Milone M.;
RT   "Rapsyn mutations in humans cause endplate acetylcholine-receptor
RT   deficiency and myasthenic syndrome.";
RL   Am. J. Hum. Genet. 70:875-885(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT LYS-8.
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   UBIQUITINATION BY THE BCR(KLHL8) COMPLEX.
RX   PubMed=19158078; DOI=10.1074/jbc.m808230200;
RA   Nam S., Min K., Hwang H., Lee H.O., Lee J.H., Yoon J., Lee H., Park S.,
RA   Lee J.;
RT   "Control of rapsyn stability by the CUL-3-containing E3 ligase complex.";
RL   J. Biol. Chem. 284:8195-8206(2009).
RN   [6]
RP   VARIANTS CMS11 PRO-14 AND LYS-88.
RX   PubMed=12730725; DOI=10.1007/s10038-003-0005-7;
RA   Dunne V., Maselli R.A.;
RT   "Identification of pathogenic mutations in the human rapsyn gene.";
RL   J. Hum. Genet. 48:204-207(2003).
RN   [7]
RP   VARIANTS CMS11 PRO-14 AND LYS-88.
RX   PubMed=12929188; DOI=10.1002/mus.10433;
RA   Maselli R.A., Dunne V., Pascual-Pascual S.I., Bowe C., Agius M., Frank R.,
RA   Wollmann R.L.;
RT   "Rapsyn mutations in myasthenic syndrome due to impaired receptor
RT   clustering.";
RL   Muscle Nerve 28:293-301(2003).
RN   [8]
RP   VARIANT CMS11 LYS-88.
RX   PubMed=12796535; DOI=10.1212/01.wnl.0000072262.14931.80;
RA   Mueller J.S., Mildner G., Mueller-Felber W., Schara U., Krampfl K.,
RA   Petersen B., Petrova S., Stucka R., Mortier W., Bufler J., Kurlemann G.,
RA   Huebner A., Merlini L., Lochmuller H., Abicht A.;
RT   "Rapsyn N88K is a frequent cause of congenital myasthenic syndromes in
RT   European patients.";
RL   Neurology 60:1805-1810(2003).
RN   [9]
RP   VARIANT CMS11 LYS-88.
RX   PubMed=14504330; DOI=10.1212/01.wnl.0000085865.55513.ae;
RA   Burke G., Cossins J., Maxwell S., Owens G., Vincent A., Robb S.,
RA   Nicolle M., Hilton-Jones D., Newsom-Davis J., Palace J., Beeson D.;
RT   "Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset
RT   phenotypes.";
RL   Neurology 61:826-828(2003).
RN   [10]
RP   VARIANT CMS11 LYS-88.
RX   PubMed=15036330; DOI=10.1016/j.nmd.2003.11.004;
RA   Banwell B.L., Ohno K., Sieb J.P., Engel A.G.;
RT   "Novel truncating RAPSN mutations causing congenital myasthenic syndrome
RT   responsive to 3,4-diaminopyridine.";
RL   Neuromuscul. Disord. 14:202-207(2004).
RN   [11]
RP   VARIANT CMS11 LYS-88.
RX   PubMed=15328566; DOI=10.1055/s-2004-820993;
RA   Ioos C., Barois A., Richard P., Eymard B., Hantai D.,
RA   Estournet-Mathiaud B.;
RT   "Congenital myasthenic syndrome due to rapsyn deficiency: three cases with
RT   arthrogryposis and bulbar symptoms.";
RL   Neuropediatrics 35:246-249(2004).
RN   [12]
RP   VARIANTS CMS11 CYS-164 AND PRO-283, AND CHARACTERIZATION OF VARIANTS CMS11
RP   CYS-164 AND PRO-283.
RX   PubMed=16931511; DOI=10.1212/01.wnl.0000233837.79459.40;
RA   Mueller J.S., Baumeister S.K., Rasic V.M., Krause S., Todorovic S.,
RA   Kugler K., Mueller-Felber W., Abicht A., Lochmueller H.;
RT   "Impaired receptor clustering in congenital myasthenic syndrome with novel
RT   RAPSN mutations.";
RL   Neurology 67:1159-1164(2006).
RN   [13]
RP   VARIANTS CMS11 MET-45 AND LYS-162, AND CHARACTERIZATION OF VARIANTS CMS11
RP   MET-45 AND LYS-162.
RX   PubMed=17594401; DOI=10.1111/j.1399-0004.2007.00824.x;
RA   Maselli R.A., Dris H., Schnier J., Cockrell J.L., Wollmann R.L.;
RT   "Congenital myasthenic syndrome caused by two non-N88K rapsyn mutations.";
RL   Clin. Genet. 72:63-65(2007).
RN   [14]
RP   INVOLVEMENT IN FADS2.
RX   PubMed=18179903; DOI=10.1016/j.ajhg.2007.09.016;
RA   Vogt J., Harrison B.J., Spearman H., Cossins J., Vermeer S., ten Cate L.N.,
RA   Morgan N.V., Beeson D., Maher E.R.;
RT   "Mutation analysis of CHRNA1, CHRNB1, CHRND, and RAPSN genes in multiple
RT   pterygium syndrome/fetal akinesia patients.";
RL   Am. J. Hum. Genet. 82:222-227(2008).
RN   [15]
RP   VARIANTS FADS2 SER-139 AND VAL-189.
RX   PubMed=18252226; DOI=10.1016/j.ajhg.2007.11.006;
RA   Michalk A., Stricker S., Becker J., Rupps R., Pantzar T., Miertus J.,
RA   Botta G., Naretto V.G., Janetzki C., Yaqoob N., Ott C.-E., Seelow D.,
RA   Wieczorek D., Fiebig B., Wirth B., Hoopmann M., Walther M., Koerber F.,
RA   Blankenburg M., Mundlos S., Heller R., Hoffmann K.;
RT   "Acetylcholine receptor pathway mutations explain various fetal akinesia
RT   deformation sequence disorders.";
RL   Am. J. Hum. Genet. 82:464-476(2008).
CC   -!- FUNCTION: Postsynaptic protein required for clustering of nicotinic
CC       acetylcholine receptors (nAChRs) at the neuromuscular junction. It may
CC       link the receptor to the underlying postsynaptic cytoskeleton, possibly
CC       by direct association with actin or spectrin.
CC   -!- INTERACTION:
CC       Q13702-2; P54253: ATXN1; NbExp=6; IntAct=EBI-22012855, EBI-930964;
CC       Q13702-2; P42858: HTT; NbExp=18; IntAct=EBI-22012855, EBI-466029;
CC       Q13702-2; Q96CV9: OPTN; NbExp=3; IntAct=EBI-22012855, EBI-748974;
CC       Q13702-2; P50454: SERPINH1; NbExp=3; IntAct=EBI-22012855, EBI-350723;
CC       Q13702-2; P37840: SNCA; NbExp=3; IntAct=EBI-22012855, EBI-985879;
CC       Q13702-2; P37173: TGFBR2; NbExp=3; IntAct=EBI-22012855, EBI-296151;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Peripheral membrane protein;
CC       Cytoplasmic side. Postsynaptic cell membrane; Peripheral membrane
CC       protein; Cytoplasmic side. Cytoplasm, cytoskeleton. Note=Cytoplasmic
CC       surface of postsynaptic membranes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13702-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13702-2; Sequence=VSP_005533;
CC   -!- DOMAIN: A cysteine-rich region homologous to part of the regulatory
CC       domain of protein kinase C may be important in interactions of this
CC       protein with the lipid bilayer.
CC   -!- PTM: Ubiquitinated by the BCR(KLHL8) complex, leading to its
CC       degradation. {ECO:0000269|PubMed:19158078}.
CC   -!- DISEASE: Myasthenic syndrome, congenital, 11, associated with
CC       acetylcholine receptor deficiency (CMS11) [MIM:616326]: A form of
CC       congenital myasthenic syndrome, a group of disorders characterized by
CC       failure of neuromuscular transmission, including pre-synaptic,
CC       synaptic, and post-synaptic disorders that are not of autoimmune
CC       origin. Clinical features are easy fatigability and muscle weakness
CC       affecting the axial and limb muscles (with hypotonia in early-onset
CC       forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and
CC       the facial and bulbar musculature (affecting sucking and swallowing,
CC       and leading to dysphonia). The symptoms fluctuate and worsen with
CC       physical effort. CMS11 is an autosomal recessive disorder of
CC       postsynaptic neuromuscular transmission, due to deficiency of AChR at
CC       the endplate that results in low amplitude of the miniature endplate
CC       potential and current. {ECO:0000269|PubMed:11791205,
CC       ECO:0000269|PubMed:12730725, ECO:0000269|PubMed:12796535,
CC       ECO:0000269|PubMed:12929188, ECO:0000269|PubMed:14504330,
CC       ECO:0000269|PubMed:15036330, ECO:0000269|PubMed:15328566,
CC       ECO:0000269|PubMed:16931511, ECO:0000269|PubMed:17594401}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Fetal akinesia deformation sequence 2 (FADS2) [MIM:618388]: A
CC       clinically and genetically heterogeneous group of disorders with
CC       congenital malformations related to impaired fetal movement. Clinical
CC       features include fetal akinesia, intrauterine growth retardation,
CC       polyhydramnios, arthrogryposis, pulmonary hypoplasia, craniofacial
CC       abnormalities, and cryptorchidism. FADS2 inheritance is autosomal
CC       recessive. {ECO:0000269|PubMed:18179903, ECO:0000269|PubMed:18252226}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the RAPsyn family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z33905; CAA83954.1; -; mRNA.
DR   EMBL; AF449218; AAL86639.1; -; mRNA.
DR   EMBL; CH471064; EAW67914.1; -; Genomic_DNA.
DR   EMBL; BC004196; AAH04196.1; -; mRNA.
DR   CCDS; CCDS7936.1; -. [Q13702-1]
DR   CCDS; CCDS7937.1; -. [Q13702-2]
DR   PIR; S45064; S45064.
DR   RefSeq; NP_005046.2; NM_005055.4. [Q13702-1]
DR   RefSeq; NP_116034.2; NM_032645.4. [Q13702-2]
DR   AlphaFoldDB; Q13702; -.
DR   SMR; Q13702; -.
DR   BioGRID; 111848; 21.
DR   IntAct; Q13702; 10.
DR   STRING; 9606.ENSP00000298854; -.
DR   ChEMBL; CHEMBL2163166; -.
DR   iPTMnet; Q13702; -.
DR   PhosphoSitePlus; Q13702; -.
DR   BioMuta; RAPSN; -.
DR   DMDM; 145559521; -.
DR   PaxDb; Q13702; -.
DR   PeptideAtlas; Q13702; -.
DR   ProteomicsDB; 59664; -. [Q13702-1]
DR   ProteomicsDB; 59665; -. [Q13702-2]
DR   Antibodypedia; 13774; 200 antibodies from 34 providers.
DR   DNASU; 5913; -.
DR   Ensembl; ENST00000298854.7; ENSP00000298854.2; ENSG00000165917.10. [Q13702-1]
DR   Ensembl; ENST00000352508.7; ENSP00000298853.3; ENSG00000165917.10. [Q13702-2]
DR   GeneID; 5913; -.
DR   KEGG; hsa:5913; -.
DR   MANE-Select; ENST00000298854.7; ENSP00000298854.2; NM_005055.5; NP_005046.2.
DR   UCSC; uc001nfi.2; human. [Q13702-1]
DR   AGR; HGNC:9863; -.
DR   CTD; 5913; -.
DR   DisGeNET; 5913; -.
DR   GeneCards; RAPSN; -.
DR   GeneReviews; RAPSN; -.
DR   HGNC; HGNC:9863; RAPSN.
DR   HPA; ENSG00000165917; Group enriched (skeletal muscle, tongue).
DR   MalaCards; RAPSN; -.
DR   MIM; 601592; gene.
DR   MIM; 616326; phenotype.
DR   MIM; 618388; phenotype.
DR   neXtProt; NX_Q13702; -.
DR   OpenTargets; ENSG00000165917; -.
DR   Orphanet; 994; Fetal akinesia deformation sequence.
DR   Orphanet; 33108; Lethal multiple pterygium syndrome.
DR   Orphanet; 98913; Postsynaptic congenital myasthenic syndromes.
DR   PharmGKB; PA34224; -.
DR   VEuPathDB; HostDB:ENSG00000165917; -.
DR   eggNOG; KOG1941; Eukaryota.
DR   GeneTree; ENSGT00390000016785; -.
DR   HOGENOM; CLU_030911_0_0_1; -.
DR   InParanoid; Q13702; -.
DR   OMA; ALRCSHI; -.
DR   OrthoDB; 893642at2759; -.
DR   PhylomeDB; Q13702; -.
DR   TreeFam; TF328344; -.
DR   PathwayCommons; Q13702; -.
DR   SignaLink; Q13702; -.
DR   SIGNOR; Q13702; -.
DR   BioGRID-ORCS; 5913; 16 hits in 1189 CRISPR screens.
DR   GeneWiki; RAPSN; -.
DR   GenomeRNAi; 5913; -.
DR   Pharos; Q13702; Tbio.
DR   PRO; PR:Q13702; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q13702; protein.
DR   Bgee; ENSG00000165917; Expressed in hindlimb stylopod muscle and 97 other tissues.
DR   ExpressionAtlas; Q13702; baseline and differential.
DR   Genevisible; Q13702; HS.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0099634; C:postsynaptic specialization membrane; IEA:Ensembl.
DR   GO; GO:0033130; F:acetylcholine receptor binding; IDA:MGI.
DR   GO; GO:0035255; F:ionotropic glutamate receptor binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043495; F:protein-membrane adaptor activity; IEA:InterPro.
DR   GO; GO:0098879; F:structural constituent of postsynaptic specialization; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:1903540; P:establishment of protein localization to postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl.
DR   GO; GO:2000673; P:positive regulation of motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:1900075; P:positive regulation of neuromuscular synaptic transmission; IBA:GO_Central.
DR   GO; GO:1901626; P:regulation of postsynaptic membrane organization; IEA:Ensembl.
DR   GO; GO:0007271; P:synaptic transmission, cholinergic; IGI:MGI.
DR   CDD; cd16478; RING-H2_Rapsyn; 1.
DR   Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 2.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR001237; Postsynaptic.
DR   InterPro; IPR018293; Postsynaptic_CS.
DR   InterPro; IPR019568; Rapsyn_myristoylation/link_N.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR041617; TPR_MalT.
DR   InterPro; IPR019734; TPR_repeat.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR46574; 43 KDA RECEPTOR-ASSOCIATED PROTEIN OF THE SYNAPSE; 1.
DR   PANTHER; PTHR46574:SF1; 43 KDA RECEPTOR-ASSOCIATED PROTEIN OF THE SYNAPSE; 1.
DR   Pfam; PF10579; Rapsyn_N; 1.
DR   Pfam; PF17874; TPR_MalT; 1.
DR   Pfam; PF13639; zf-RING_2; 1.
DR   PRINTS; PR00217; POSTSYNAPTIC.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00028; TPR; 7.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   SUPFAM; SSF48452; TPR-like; 2.
DR   PROSITE; PS00405; 43_KD_POSTSYNAPTIC; 1.
DR   PROSITE; PS50005; TPR; 5.
DR   PROSITE; PS50293; TPR_REGION; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Congenital myasthenic syndrome;
KW   Cytoplasm; Cytoskeleton; Disease variant; Lipoprotein; Membrane;
KW   Metal-binding; Myristate; Phosphoprotein; Postsynaptic cell membrane;
KW   Reference proteome; Repeat; Synapse; TPR repeat; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT   CHAIN           2..412
FT                   /note="43 kDa receptor-associated protein of the synapse"
FT                   /id="PRO_0000167591"
FT   REPEAT          6..39
FT                   /note="TPR 1"
FT   REPEAT          83..116
FT                   /note="TPR 2"
FT   REPEAT          123..156
FT                   /note="TPR 3"
FT   REPEAT          163..196
FT                   /note="TPR 4"
FT   REPEAT          206..239
FT                   /note="TPR 5"
FT   REPEAT          246..279
FT                   /note="TPR 6"
FT   REPEAT          286..319
FT                   /note="TPR 7"
FT   ZN_FING         363..403
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   MOD_RES         196
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         405
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         264..322
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_005533"
FT   VARIANT         8
FT                   /note="Q -> K (in dbSNP:rs11556408)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_043897"
FT   VARIANT         14
FT                   /note="L -> P (in CMS11; dbSNP:rs104894300)"
FT                   /evidence="ECO:0000269|PubMed:11791205,
FT                   ECO:0000269|PubMed:12730725, ECO:0000269|PubMed:12929188"
FT                   /id="VAR_021216"
FT   VARIANT         45
FT                   /note="V -> M (in CMS11; reduced coclustering with
FT                   acetylcholine receptor; dbSNP:rs121909254)"
FT                   /evidence="ECO:0000269|PubMed:17594401"
FT                   /id="VAR_043898"
FT   VARIANT         81
FT                   /note="F -> L (in dbSNP:rs57878668)"
FT                   /id="VAR_062142"
FT   VARIANT         88
FT                   /note="N -> K (in CMS11; dbSNP:rs104894299)"
FT                   /evidence="ECO:0000269|PubMed:11791205,
FT                   ECO:0000269|PubMed:12730725, ECO:0000269|PubMed:12796535,
FT                   ECO:0000269|PubMed:12929188, ECO:0000269|PubMed:14504330,
FT                   ECO:0000269|PubMed:15036330, ECO:0000269|PubMed:15328566"
FT                   /id="VAR_021217"
FT   VARIANT         139
FT                   /note="F -> S (in FADS2; dbSNP:rs121909256)"
FT                   /evidence="ECO:0000269|PubMed:18252226"
FT                   /id="VAR_043899"
FT   VARIANT         162
FT                   /note="E -> K (in CMS11; reduced coclustering with
FT                   acetylcholine receptor; dbSNP:rs121909255)"
FT                   /evidence="ECO:0000269|PubMed:17594401"
FT                   /id="VAR_043900"
FT   VARIANT         164
FT                   /note="R -> C (in CMS11; reduced coclustering with
FT                   acetylcholine receptor; dbSNP:rs104894294)"
FT                   /evidence="ECO:0000269|PubMed:16931511"
FT                   /id="VAR_043901"
FT   VARIANT         189
FT                   /note="A -> V (in FADS2; dbSNP:rs121909257)"
FT                   /evidence="ECO:0000269|PubMed:18252226"
FT                   /id="VAR_043902"
FT   VARIANT         283
FT                   /note="L -> P (in CMS11; reduced coclustering with
FT                   acetylcholine receptor; dbSNP:rs104894293)"
FT                   /evidence="ECO:0000269|PubMed:16931511"
FT                   /id="VAR_043903"
FT   CONFLICT        112
FT                   /note="L -> V (in Ref. 1; CAA83954)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        159
FT                   /note="A -> T (in Ref. 1; CAA83954)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        205
FT                   /note="R -> Q (in Ref. 1; CAA83954)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        364
FT                   /note="G -> A (in Ref. 1; CAA83954)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   412 AA;  46328 MW;  D17AC566700F5AAF CRC64;
     MGQDQTKQQI EKGLQLYQSN QTEKALQVWT KVLEKSSDLM GRFRVLGCLV TAHSEMGRYK
     EMLKFAVVQI DTARELEDAD FLLESYLNLA RSNEKLCEFH KTISYCKTCL GLPGTRAGAQ
     LGGQVSLSMG NAFLGLSVFQ KALESFEKAL RYAHNNDDAM LECRVCCSLG SFYAQVKDYE
     KALFFPCKAA ELVNNYGKGW SLKYRAMSQY HMAVAYRLLG RLGSAMECCE ESMKIALQHG
     DRPLQALCLL CFADIHRSRG DLETAFPRYD SAMSIMTEIG NRLGQVQALL GVAKCWVARK
     ALDKALDAIE RAQDLAEEVG NKLSQLKLHC LSESIYRSKG LQRELRAHVV RFHECVEETE
     LYCGLCGESI GEKNSRLQAL PCSHIFHLRC LQNNGTRSCP NCRRSSMKPG FV
//
